Incremental Value of Echocardiography in Patients With or Without Hypertension
Which (Death)Star to Hitch the Wagon?
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
See related article, pp 742–751
Hypertension is the most prevalent risk factor for ischemic heart disease, heart failure, and stroke.1 Several studies have shown that measures of cardiac target organ damage are independent predictors of increased cardiovascular morbidity and mortality.2–4 Left ventricular (LV) hypertrophy was one of the first measures of cardiac target organ damage to have been shown to predict adverse cardiac events in patients with hypertension.2 Subsequently, other measures of cardiac target organ damage have been implicated in predicting adverse outcomes in population-based and selected clinical populations including patients with hypertension.3,4 More recently, global longitudinal strain (GLS)—an automated echocardiographic technique for measurement of long-axis systolic function—has been shown to predict adverse events in population-based and selected clinical populations.5,6
Echocardiography has been extensively utilized in clinical and epidemiological studies to evaluate cardiac target organ damage because of its availability, ease of …